Monday, December 9, 2024

CATEGORY

GSK

Blenrep Combinations Await FDA Decision for Multiple Myeloma Treatment

GSK plc has taken a significant step in advancing treatment options for relapsed or refractory multiple myeloma by submitting a Biologics License Application (BLA)...

Arexvy Now Protecting Japanese Adults 50-59 from Severe RSV

GSK plc has successfully secured approval from Japan's Ministry of Health, Labor and Welfare (MHLW) to extend the use of its respiratory syncytial virus...

GSK’s Linerixibat Significantly Reduces Itching in PBC Patients in Phase III Trial

GSK plc unveiled promising results from its Phase III GLISTEN trial, showcasing linerixibat's effectiveness in alleviating chronic itching among individuals with primary biliary cholangitis...

How the 2024 Access to Medicine Index Exposes Industry Gaps and Opportunities in Global Health Equity

Key TakeawaysNovartis ranks first, with GSK following closely, yet overall progress in access to essential medicines remains stagnant. Only 43% of clinical trials...

GSK Strengthens Immunology Lineup with $300 Million Acquisition of Chimagen’s CMG1A46

Key TakeawaysGSK's acquisition solidifies its position in the autoimmune disease treatment space.  CMG1A46 offers a novel approach targeting both CD19 and CD20, potentially...

GSK Expands RSV Vaccine Reach with New Promising Data

GSK has unveiled groundbreaking data on its Arexvy vaccine, offering hope for expanding protection against respiratory syncytial virus (RSV) to a wider demographic. This...

GSK’s Gepotidacin Receives Priority FDA Review as First New Oral Antibiotic for uUTIs in Over 20 Years

Key TakeawaysGepotidacin, a novel oral antibiotic, has been accepted by the FDA for priority review, potentially becoming the first new treatment for uncomplicated...

GSK and Cambridge University Forge New Path in Immune Related Diseases Research

Key TakeawaysGSK and the University of Cambridge announce a five-year partnership to develop therapies for kidney and respiratory diseases using immunology and AI. ...

GSK and ViiV Healthcare to Showcase Breakthroughs in Infectious Disease at IDWeek 2024

Key TakeawaysGSK and ViiV Healthcare will present 60 abstracts at IDWeek 2024, showcasing innovations in vaccines and therapeutics, including solutions for HIV, antimicrobial...

GSK’s Depemokimab Shows Promise for Treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Phase III ANCHOR Trials

Key TakeawaysGSK's depemokimab, administered biannually, demonstrated significant reduction in nasal polyp size and nasal obstruction in patients with chronic rhinosinusitis with nasal polyps...

Important Notice for Healthcare Professionals Regarding Infanrix Hexa Needle Soft Packs

Key TakeawaysA packaging issue affecting the sterility of needle soft packs included with Infanrix Hexa pediatric vaccines has been identified. The defect involves...

Respiratory Syncytial Virus Vaccine Arexvy Shows Promising Results for Older Adults in Phase 3 Trial

Key TakeawaysRespiratory syncytial virus poses a significant health risk for older adults, and GSK's Arexvy vaccine has shown promising efficacy of 62.9% against...

HIV Epidemic Tackled with ViiV Healthcare’s Expanded Access to CAB LA for PrEP

Key TakeawaysHIV epidemic prevention efforts are being strengthened as ViiV Healthcare triples its supply of long-acting cabotegravir for PrEP to low- and middle-income...

Vaccine Update: GSK’s Menveo Meningococcal Vaccine Receives Positive CHMP Opinion for New Single-Vial Presentation

Key TakeawaysGSK’s Menveo (MenACWY) receives a positive opinion for a fully liquid, single-vial presentation from the EMA. If approved, this version will simplify...

Medicare Set to Include COPD Drugs in Next Round of Price Negotiations, ICER Prepares Evaluation

Key TakeawaysThe next round is expected to target COPD drugs like GSK's Breo Ellipta and Trelegy Ellipta. ICER is preparing a special report...

Latest news